RESEARCH: HALOGENASES
FOLDING PROJECT #19209 PROFILE

Many drugs use halogens (like fluorine). Making these halogens stick in the right spot on a drug molecule is tricky. Scientists are studying special enzymes called halogenases that can do this job better than current methods, with fewer harmful side effects. This project uses computer models to predict how well different halogenases work on common drug building blocks.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

halogen

Elements fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

Halogens are highly reactive elements frequently used in drug development. They can modify a molecule's properties, influencing its effectiveness and interaction with biological targets. However, controlling halogenation reactions can be challenging due to potential toxicity and selectivity issues.

---

pharmaceutically active ligand

A molecule that binds to a biological target (e.g., receptor) and elicits a pharmacological response.

A pharmaceutically active ligand is a crucial component of many drugs. These molecules interact with specific targets within the body, triggering desired effects such as pain relief, inflammation reduction, or infection control.

---

scaffold

A basic structural framework for a molecule that can be modified to create various drug candidates.

In drug development, a scaffold serves as the foundation upon which chemists build new molecules. By modifying different parts of the scaffold, scientists can fine-tune a molecule's properties and target specific biological pathways.

---

regioselectivity

The preference of a chemical reaction to occur at a specific position on a molecule.

Regioselectivity is crucial in chemical reactions, especially when synthesizing complex molecules like drugs. It ensures that the desired modifications occur at the intended locations, maximizing efficiency and minimizing unwanted byproducts.

---

halogenases

Enzymes that catalyze the regioselective halogenation of organic molecules.

Halogenases are fascinating enzymes found in nature. They possess the remarkable ability to introduce halogens (e.g., fluorine, chlorine) into specific positions within organic molecules with high precision. Researchers are exploring their potential for developing greener and more efficient methods for synthesizing pharmaceuticals.

---

Relative Binding Free Energy (RBFE)

A computational method used to predict the binding affinity of a molecule to a target.

RBFE calculations are valuable tools in drug discovery. By simulating the interactions between a potential drug and its target, researchers can assess the strength of binding and identify promising candidates for further development.